Los Angeles Biotechnology Network
Advertise With Biotech Networks
  • Home
  • About
  • News
    • All LABN News
    • Trending LABN News
  • Jobs
    • All LABN Jobs
    • Post A Job
  • Subscribe
  • Contact
News Ticker
  • [ October 3, 2023 ] Serimmune Announces Use of Its SERA Platform in Study Designed to Identify Features of Long COVID Through Immune Profiling Los Angeles Biotech News
  • [ October 3, 2023 ] ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa Los Angeles Biotech News
  • [ October 3, 2023 ] Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies Los Angeles Biotech News
  • [ October 3, 2023 ] BioBam Launches OmicsBox 3.1: Revolutionizing Omics Data Analysis Los Angeles Biotech News
  • [ October 3, 2023 ] Ark Electronics Receives ISO 13485 Certification for Medical Equipment Manufacturing Los Angeles Biotech News
HomeLos Angeles Biotech NewsNeumora, with Arch and Amgen in its corner, files for IPO to fund late-phase depression clinical trials

Neumora, with Arch and Amgen in its corner, files for IPO to fund late-phase depression clinical trials

August 28, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Neumora, with Arch and Amgen in its corner, files for IPO to fund late-phase depression clinical trials

Neumora, with Arch and Amgen in its corner, files for IPO to fund late-phase depression clinical trials
ntaylor
Mon, 08/28/2023 – 09:10
Click here to view original post

Previous

Tyson 2.0’s ‘Solventless Mike Bites’: The New Gold Standard in Edibles

Next

FTC pauses challenge of Amgen’s $28B Horizon takeover to consider settlement

Follow/Subscribe

Advertise With Biotech Networks
POST A JOB
Tweets by LABioNetwork
Advertise With Biotech Networks

Copyright © 2023 Biotech Networks, LLC

Want to Save Time?

Get Trending News & Jobs Delivered